Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for ExpreS2ion Biotech Holding AB's PB Ratio or its related term are showing as below:
OSTO:EXPRS2'
s PB Ratio Range Over the Past 10 Years
Min: 0.46 Med: 4.33 Max: 289.83
Current: 0.55
During the past 13 years, ExpreS2ion Biotech Holding AB's highest PB Ratio was 289.83. The lowest was 0.46. And the median was 4.33.
OSTO:EXPRS2's PB Ratio is ranked better than 93.89% of 1228
companies
in the Biotechnology industry
Industry Median: 2.885
vs OSTO:EXPRS2: 0.55
During the past 12 months, ExpreS2ion Biotech Holding AB's average Book Value Per Share Growth Rate was -61.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -51.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -39.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ExpreS2ion Biotech Holding AB was 91.70% per year. The lowest was -51.30% per year. And the median was 19.70% per year.
Back to Basics: PB Ratio
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ExpreS2ion Biotech Holding AB PB Ratio Related Terms
ExpreS2ion Biotech Holding AB PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:EXPRS2 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ExpreS2ion Biotech Holding AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where ExpreS2ion Biotech Holding AB's PB Ratio falls into.
ExpreS2ion Biotech Holding AB PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) has a PB Ratio of 0.55 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ExpreS2ion Biotech Holding AB and its competitors. This is 87% below median its historical median of 4.33. Over the past decade, ExpreS2ion Biotech Holding AB's PB Ratio has ranged from 0.46 to 289.83. According to the industry distribution chart, ExpreS2ion Biotech Holding AB ranks #75 out of 1228 companies in the Biotechnology industry, placing it in the top 6.1%.
Is ExpreS2ion Biotech Holding AB's PB Ratio too high?
ExpreS2ion Biotech Holding AB's current PB Ratio of 0.55 is 87% below median its 10-year median of 4.33. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 289.83. The Biotechnology industry median PB Ratio is 2.89. ExpreS2ion Biotech Holding AB's value of 0.55 is 80.9% below this industry median. Based on the distribution chart, ExpreS2ion Biotech Holding AB ranks #75 out of 1228 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ExpreS2ion Biotech Holding AB ranks #75 out of 1228 companies for PB Ratio. This places ExpreS2ion Biotech Holding AB in the top 6% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.89. ExpreS2ion Biotech Holding AB's value of 0.55 is 80.9% below this benchmark. Historically, ExpreS2ion Biotech Holding AB's own PB Ratio has ranged from 0.46 to 289.83 over the past decade. While the company's 10-year median is 4.33 vs. the industry median of 2.89, ExpreS2ion Biotech Holding AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ExpreS2ion Biotech Holding AB's current PB Ratio of 0.55 is 80.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ExpreS2ion Biotech Holding AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ExpreS2ion Biotech Holding AB's current PB Ratio is 0.55, which is 87% below median its own 10-year median of 4.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) is currently considered Possible Value Trap. The stock's GF Value™ is kr3.43, compared to a current price of kr1.46 — trading 57.4% below its estimated fair value. The current PB Ratio is 0.55, which is 87% below median its 10-year median of 4.33 and 80.9% below the Biotechnology industry median of 2.89. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (OSTO:EXPRS2), the current PB Ratio is 0.55 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Overvalued in 2026?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued.
The current stock price of kr1.46 is trading 57.4% below its estimated GF Value™ of kr3.43.
GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.
Key valuation signals for OSTO:EXPRS2:
PB Ratio: 0.55 (87% below median its 10-year median of 4.33)
GF Value™: kr3.43 vs. price of kr1.46 (57.4% below fair value)
Industry Position: 80.9% below the Biotechnology median (#75 of 1228)
No single metric tells the full story. See the OSTO:EXPRS2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ExpreS2ion Biotech Holding AB Business Description
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score
Get the complete analysis for OSTO:EXPRS2
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EXPRS2 has been successfully added to your 
